Skip to Content Facebook Feature Image

LifeSpan Vision Ventures Invests in Remedium Bio

Business

LifeSpan Vision Ventures Invests in Remedium Bio
Business

Business

LifeSpan Vision Ventures Invests in Remedium Bio

2024-09-10 22:17 Last Updated At:22:35

NORWALK, Conn., Sept. 10, 2024 /PRNewswire/ -- LifeSpan Vision Ventures today announced that it has closed an investment in Remedium Bio.  

The biotechnology company is developing a first-in-class adjustable-dose gene therapy platform called Prometheusâ„¢, which can replace a broad range of multi-protein injection treatments with a single injection, dose adjustable, gene therapy. The treatment, which is administered by a subcutaneous injection, is highly safe, localized, durable, and costs less than many protein-based therapeutics. Unlike with therapeutic protein injections, Prometheusâ„¢ delivers stable, durable, and consistent protein expression, eliminating the concentration spikes that can limit the safety and efficacy of treatments delivered via repeat injection.

The funding will be used to advance the company's lead candidate, RMD-1202, towards Phase 1 studies. RMD-1202 delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections - with a potentially increased safety and tolerability profile. The platform can deliver a broad range of proteins, from peptides to antibodies and Remedium is developing additional therapies across musculoskeletal, immunology, and neurology disorders.  

Andrew Worden, Founding Partner at LifeSpan Vision Ventures, said "Our mission is to invest in companies that support and accelerate the development of therapies that extend healthspan and address age-related challenges. We believe that Remedium's technology can be applied across a broad range of age-related diseases and opens the potential of gene therapy to vast markets. We are delighted to be supporting Frank and his team to take the company to the next level."

Frank Luppino, President and CEO of Remedium, stated "We are extremely excited to welcome Lifespan Vision Ventures as an investor in Remedium Bio. Our Prometheusâ„¢ platform is a significant advance in genetic medicine, one that brings the benefits of gene therapy to large unmet needs affecting how we age. Lifespan, with their strong grounding in the science and experience growing innovative companies, is an ideal partner to support Remedium as we enter an exciting new phase in our evolution."

About Remedium Bio

Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheusâ„¢ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium's pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.

For more information, visit https://www.remedium-bio.com/

About LifeSpan Vision Ventures

LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend healthspan, improve the quality of life for individuals as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience, and endless possibilities.

Contact: Harry Robb, Analyst: harry.robb@lifespanvision.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

LifeSpan Vision Ventures Invests in Remedium Bio

LifeSpan Vision Ventures Invests in Remedium Bio

SHENZHEN, China, Jan. 20, 2025 /PRNewswire/ -- CHIGEE, the innovative motorcycle riding system manufacturer, announces its first-ever appearance at AIMExpo 2025, North America's premier powersports trade show. From February 5-7, 2025, CHIGEE will showcase its complete product lineup alongside the highly anticipated AIO-6 at the Las Vegas Convention Center's South Hall, booth #8088.

"We're looking forward to meeting with riders and industry professionals at AIMExpo," said the CHIGEE team. "This event provides an excellent opportunity to showcase our advanced riding systems and develop our distribution network in North America."

The CHIGEE team will be available throughout the show for product demonstrations and technical consultations. As part of our North American expansion, we welcome distributors and dealers to explore partnership opportunities. Interested parties can apply via this form.

Show attendees can experience hands-on demonstrations of CHIGEE's full product range, including a preview of the new AIO-6 system. The new AIO-6 introduces a larger 6-inch screen with all-new UI design, bringing riders a more intuitive and clearer navigation experience. To stay updated on product launches and show specials, follow CHIGEE on Facebook or visit the official website.

Event Details:

Launching in 2024 with Apple CarPlay and Android Auto integration, the CHIGEE AIO-5 series embodies a clear mission: bringing smart technology to all riders. This versatile system fits most motorcycles and provides essential features like real-time navigation and sunset times to better plan your trip. Equipped with comprehensive dash cam features, the top-tier AIO-5 Lite safeguards your rides by recording and storing vital video evidence.

Riders are finding their journeys truly improved with CHIGEE's innovative smart system. "As a daily commuter and weekend touring enthusiast, CHIGEE's system has been a game-changer for me. The GPS navigation is crystal clear even in bright sunlight, and I no longer need to stop every time I get a message - CarPlay handles that seamlessly. The dash cam gives me extra peace of mind, especially during group rides. It's like upgrading from a flip phone to a smartphone - you don't realize how much you needed it until you have it." — Touring enthusiast, California, USA.

To schedule a meeting at AIMExpo 2025 or learn more about CHIGEE products, please visit chigee.com or contact press@chigeego.com. For media inquiries, including high-resolution product images, company details, and technical specifications, please visit our press room.

About CHIGEE

CHIGEE, founded in 2020, pioneers motorcycle smart technology. The name CHIGEE derives from 'riding technology' in Chinese, reflecting the company's mission to create innovative devices that transform riding experiences. With extensive R&D and global testing, CHIGEE delivers exceptional products for riders worldwide.

Facebook: Chigee Global
Instagram: @chigeeglobal
Youtube: Chigee Official

Contact Information
CHIGEE PR Team
Email: press@chigeego.com
Website: www.chigee.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

CHIGEE to Debut at 2025 AIMExpo with Full Product Line, Expanding North American Market

CHIGEE to Debut at 2025 AIMExpo with Full Product Line, Expanding North American Market

Recommended Articles
Hot · Posts